Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment
Treatments to slow the progression of cognitive dysfunction to dementia and improve the quality of life of persons with Parkinson's disease (PD) are desperately needed. Because PD mild cognitive impairment is considered a transitional stage before dementia, it opens a window to timely intervention. This article critically reviews the strengths and challenges of pharmacologic and nonpharmacologic clinical therapeutic trials in PD mild cognitive impairment conducted during the past 5 years, including ongoing trials. Relatively few high-quality trials have been conducted, and some important factors in designing future clinical trials are discussed. © 2018 International Parkinson and Movement Disorder Society.
Digital Object Identifier (DOI)
Litvan, Irene; Kieburtz, Karl; Tröster, Alexander I.; and Aarsland, Dag, "Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment" (2018). Clinical Neuropsychology. 125.